Explore

Companies

Drugs

About·Data Management·Terms·Privacy

Stay informed

© 2026 VivoSeq. All rights reserved.

Cu-DOTA-ECL1i

Phase 1Small molecule

WWashington University School of Medicine

1

Indications

1

Total Trials

1

Active Trials

0

Competitors

Pipeline

Status by Indication[3][1]

Indication

Lung InflammationRecruiting

Lung InflammationPhase 1

Recruiting

Timeline

Expected Milestones

Q4 2026

Phase 1Recruiting

Lung Inflammation

NCT03492762

Clinical

Trials by Indication[1]

Lung Inflammation1 trial

PET Imaging CCR2 in Lung Inflammation

Recruiting·WWashington University School of Medicine·Phase 1·NCT03492762·110 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for Cu-DOTA-ECL1i. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Cu-DOTA-ECL1i compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Cu-DOTA-ECL1i. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Washington University School of Medicine company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 1[1]
Company: WWashington University School of Medicine

Related News